| Document |
Document Title |
|
WO/2024/090562A1 |
Provided is a method for producing a glutamate dehydrogenase of which the coenzyme is FAD. Also provided is a FAD-dependent glutamate dehydrogenase having a specified amino acid substitution.
|
|
WO/2024/088538A1 |
The invention relates to methods for diagnosing, predicting disease development, disease progression and/or disease outcome, predicting susceptibility to treatment and/or classification in the context of diseases or disorders of the fema...
|
|
WO/2024/092138A1 |
Methods for disease risk assessment using multiple data sources, and computer programs for implementing same.
|
|
WO/2024/091123A1 |
The invention relates to means and methods for analysis of target analytes using nanopore-based sensors, more in particular to methods, nanopore systems and devices for single-molecule profiling of polymers, e.g. polypeptide or polysacch...
|
|
WO/2024/088864A1 |
The invention is directed to a method for determining the spatial localisation and a sequence of interest of at least a part of at least one RNA strand comprising the steps a. providing a plurality of oligonucleotides comprising a unit c...
|
|
WO/2024/091186A1 |
The current invention relates to a method of quantitatively determining the concentration of active myrosinase in a sample, the method comprising the steps of (a) adding a portion of the sample comprising active myrosinase to a first ana...
|
|
WO/2024/089063A1 |
The present invention refers to an in vitro method for predicting the prognosis of renal carcinoma, for predicting the benefit of patients suffering from renal carcinoma from a treatment with antibody-based immunotherapy and/or for decid...
|
|
WO/2024/092189A2 |
The present disclosure provides compositions and methods related to nucleic acid sensors. In particular, the present disclosure provides nucleic acids molecules that target transcripts of a gene or chromosomal fusion and activate a downs...
|
|
WO/2024/091936A1 |
A fluidic device, instrument, and method for processing a biological sample is disclosed herein. An example of the fluidic device includes structures (e.g., sample holder(s), reaction chamber(s), reagent storage zone(s), metering compart...
|
|
WO/2024/091807A1 |
The present disclosure provides systems and methods for detecting the presence of colonies on agar plates. The systems and methods are suitably useful for evaluating the presence of a contaminant (e.g., bacterial, fungal, etc.) in a samp...
|
|
WO/2024/091883A2 |
Provided herein are methods of sex-sorting a plurality of insects based on sex-specific gene expression, the method comprising (a) generating an exogenous nucleic acid molecule; (b) delivering the exogenous nucleic acid molecule into an ...
|
|
WO/2024/089270A2 |
The present invention relates to novel pore monomers, pores formed from the pore monomers and their uses in analyte detection and characterisation.
|
|
WO/2024/091028A1 |
The present invention relates to a system and method for more effectively determining a health status and diagnosing and predicting diseases by utilizing epigenome and mutation information of cfDNA fragments in body fluids and cfDNA frag...
|
|
WO/2024/090805A1 |
The present invention relates to methylation markers and combinations thereof for diagnosing lung cancer. More specifically, the present invention relates to methylation markers that specifically show decreased or increased methylation i...
|
|
WO/2024/092151A1 |
Provided herein is a method for analyzing cells. In some embodiments the method may comprise base editing a target gene in a population of cells to produce genetically modified cells, reverse transcribing mRNA from single cells in the po...
|
|
WO/2024/090514A1 |
A three-dimensional skin model according to one embodiment of the present invention comprises: a first layer including keratinocytes or cells with differentiated keratinocytes; a second layer including dermal fibroblasts; and an intermed...
|
|
WO/2024/092169A2 |
Various embodiments are directed to analyzing host gene expression levels and microbial diversity in a biological sample, to determine a likelihood of lower-respiratory tract infection (LRTI) in subjects. Embodiments can include determin...
|
|
WO/2024/091020A1 |
The present invention relates to an extracellular vesicle-derived miRNA gene biomarker for breast cancer diagnosis or recurrence prediction and to a use thereof and, more specifically, provides an miRNA gene biomarker associated with bre...
|
|
WO/2024/091905A2 |
Cas protein variants with improved specificity against mismatches between the guide RNA and an RNA target of interest are described. Also described are novel in-silico strategies for designing high specificity Cas variants, a method of d...
|
|
WO/2024/086949A1 |
A method of isolating and purifying double stranded RNA (dsRNA) from a sample includes treating a crude RNA extract containing dsRNA obtained from a sample with a B2 dsRNA-binding protein to form a B2-dsRNA mixture containing a B2-dsRNA ...
|
|
WO/2024/091998A1 |
Systems, methods, and devices disclosed herein provide antibiotic resistance predictions using a pan-antibiotic resistance prediction (PARP) model. The PARP model includes a machine learning system trained with a training data set of gen...
|
|
WO/2024/087336A1 |
Disclosed in the present invention are an all-genetically encoded NMN protein probe based on resonance energy transfer, and a use thereof, and particularly, an all-genetically encoded NMN protein probe, which is formed by connecting a re...
|
|
WO/2024/089180A1 |
The present invention relates to a method to determine the recovery rate of sample extracellular vesicles. The present invention further relates to a kit comprising a control extracellular vesicle. The present invention also relates to m...
|
|
WO/2024/050275A3 |
The present disclosure relates to a method of enzymatically repairing RNAs that are nicked or at least partially cleaved. The method comprises providing a biological sample containing RNAs that are nicked or at least partially cleaved; p...
|
|
WO/2024/091053A1 |
The present invention relates to a method for predicting the response to immunotherapeutic agents, comprising a step of measuring, in cancer cells or cancer tissue, the expression level of a dexamethasone-induced ras-related protein 1 (D...
|
|
WO/2024/089297A1 |
Disclosed are methods to obtain enhanced variants of fluorescent and bioluminescent proteins based on ratiometric measurement of luminescence. Disclosed are furthermore engineered variants of a yellow fluorescent protein (YFP) derived fr...
|
|
WO/2024/086891A1 |
The present invention relates generally to the identification and/or treatment of cancer and in particular cancers in which gastrin releasing peptide receptor (GRPR) is expressed. In particular embodiments, the present invention relates ...
|
|
WO/2024/087602A1 |
An isothermal amplification detection device, comprising a temperature control platform (100), a reaction platform (200), a plurality of first heat conduction members (300), and a plurality of second heat conduction members (400). The te...
|
|
WO/2024/090863A1 |
The present specification provides a method for predicting the prognosis of endometrial cancer and a kit using same, the method comprising the steps of: detecting whether MSH2 or MSH6 is deficient in a biological sample isolated from an ...
|
|
WO/2024/090872A1 |
The present invention relates to a method and a kit for rapidly diagnosing tsutsugamushi on the basis of genetic scissors. More specifically, the present invention relates: to a molecular diagnosis method for rapidly detecting Orientia t...
|
|
WO/2024/091598A1 |
A nucleotide sequencing device includes a plurality microfluidic chips configured for nucleic acid sequencing and a reagent dispensing manifold with at least one dispensing port wherein the manifold is operable to move in at least two di...
|
|
WO/2023/244680A3 |
Disclosed are peptides that differentially bind to analytes, and methods for obtaining the peptides. Disclosed are methods for determining binding of peptides to analytes by detecting nucleic acids that are associated with the peptides. ...
|
|
WO/2024/091026A1 |
Provided is an electrode for detecting an extracellular matrix-degrading enzyme, the electrode specifically binding to an extracellular matrix-degrading enzyme and having excellent adsorption selectivity. One embodiment of the present in...
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
|
WO/2024/091909A1 |
Described are methods of inducing a protective immune response against Lassa virus comprising administering a prophylactically effective amount of a nucleic acid molecule encoding a Lassa virus glycoprotein precursor (LASV GPC) to a subj...
|
|
WO/2024/089673A1 |
Biomarkers that can be used for the detection and/or aid in the diagnosis of disease states, preferably pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), PH in chro...
|
|
WO/2024/089242A1 |
The invention also relates to the use of a kit or a process according to the invention for the detection of a target nucleic acid and for the diagnosis of a disease or a condition. A kit and a method according to the present invention ar...
|
|
WO/2024/090864A1 |
Provided in the present specification are a method for diagnosing endometrial cancer using a nectin-4 expression rate, and a kit using same, the method comprising the steps of: measuring a nectin-4 expression rate in a biological sample ...
|
|
WO/2024/091124A1 |
The present disclosure relates to systems and methods for analysis of proteins, more in particular to nanopore systems, devices and methods for single- molecule protein analysis and sequencing. Provided is a method for translocating a ta...
|
|
WO/2024/089437A1 |
There is provided methods for diagnosing or aiding diagnosis of pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), and/or chronic thromboembolic pulmonary hypertension (CTEPH) in a subject, determining a subject's risk o...
|
|
WO/2024/086899A1 |
The present disclosure relates to a method of separation of charged substances by electrophoresis by using an inorganic thread. It includes contacting an electrolyte with an outer surface of the inorganic thread to cause wetting the oute...
|
|
WO/2024/091874A1 |
Disclosed herein are compositions comprising a MTRES1 gene therapy. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a MTRES1 gene therapy.
|
|
WO/2024/092158A1 |
Methods of preparing stabilized cell-free nucleic acid control material in a body fluid are provided. Compositions including stabilized cell-free nucleic acid control materials and methods of their use are also provided. Kits including t...
|
|
WO/2024/091573A1 |
Disclosed are systems and methods for rapidly generating general reaction conditions using a closed-loop workflow leveraging matrix down-selection, machine learning, and robotic experimentation. In certain aspects, provided is a method, ...
|
|
WO/2024/091990A1 |
Described are methods of treating human papillomavirus (HPV) type 16- or HPV type 18-related High-grade Squamous Intraepithelial Lesion (HSIL) of the cervix. The described methods comprise evaluating one or more biological samples for th...
|
|
WO/2024/092190A2 |
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respir...
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
|
WO/2024/064803A3 |
This disclosure contemplates tagging cells or vesicles with agents using a tension activated device. In certain embodiments, a solid surface is conjugated to a double stranded nucleic acid complex wherein a first strand is conjugated to ...
|
|
WO/2024/064631A3 |
Described herein are aspects for color correction of flow cell images acquired from different channels for making accurate base calling during DNA sequencing. An aspect begins by receiving a plurality of flow cell images and determining ...
|
|
WO/2024/087405A1 |
A Cas mutant protein. Compared with a parent Cas protein, the Cas mutant protein has a significantly improved editing activity and broad application prospects.
|
